Summary:
Click image to enlargeThe LunAIRo Study (APC-APN-304) is a randomized, double blind, placebo-controlled, parallel-arm 1-year study of AD109 vs placebo in participants with mild to severe OSA who are intolerant of, or currently refuse, PAP. A screening visit and PSG will be conducted to establish, in combination with patient-reported outcomes assessments (PROs) and other criteria, that each participant meets study enrollment criteria.
Qualified Participants Must:
• 18 years and older
•
BMI must be between 18.5-40 (Men)
•
BMI must be between 18.5-42 (women)
•
Female participants need to be on contraceptive
Qualified Participants May Receive:
Participarticipes will get a break down of $1,790.